UniProt Q9H3Y6 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: aa 215-endmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 100.0% | 0.0% | 78.23 | 0.534 |
| 2 | Vemurafenib | 95.3% | 4.7% | 96.49 | 0.598 |
| 3 | Dasatinib | 91.0% | 9.1% | 87.97 | 0.699 |
| 4 | Ibrutinib | 89.7% | 10.3% | 94.74 | 0.723 |
| 5 | Tivozanib | 85.2% | 14.8% | 92.42 | 0.673 |
| 6 | Dabrafenib | 79.3% | 20.7% | 94.74 | 0.633 |
| 7 | Cabozantinib | 74.5% | 25.5% | 92.73 | 0.751 |
| 8 | Zanubrutinib | 54.0% | 46.0% | 98.24 | 0.788 |
| 9 | Bosutinib | 52.6% | 47.4% | 87.22 | 0.555 |
| 10 | Brigatinib | 45.0% | 55.0% | 82.96 | 0.513 |
| 11 | Alectinib | 38.2% | 61.8% | 95.49 | 0.651 |
| 12 | Encorafenib | 33.5% | 66.5% | 98.50 | 0.755 |
| 13 | Repotrectinib | 31.1% | 68.9% | 84.21 | 0.608 |
| 14 | Mobocertinib | 28.3% | 71.7% | 97.22 | 0.757 |
| 15 | Canertinib | 23.6% | 76.4% | 96.49 | 0.671 |
| 16 | Pacritinib | 22.9% | 77.1% | 88.64 | 0.452 |
| 17 | Quizartinib | 21.8% | 78.2% | 99.50 | 0.737 |
| 18 | Crizotinib | 17.5% | 82.5% | 91.39 | 0.581 |
| 19 | Lorlatinib | 13.1% | 86.9% | 97.24 | 0.694 |
| 20 | Leniolisib | 13.0% | 87.0% | 100.00 | 0.604 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.06
- Epithelial log2(TPM+1): 1.17
- Fold change: -1.11
- Status: Downregulated
High-confidence drugs
- Vemurafenib — inh 95.3% · KISS 37.68
- Ibrutinib — inh 89.7% · KISS 37.56
- Dasatinib — inh 91.0% · KISS 32.46
Selectivity landscape vs inhibition on SRMS
Each point is one of the 92 approved drugs; color = inhibition % on SRMS.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…